{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:31:46Z","timestamp":1786116706428,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"FightMND","award":["DIS-202303-00932"],"award-info":[{"award-number":["DIS-202303-00932"]}]},{"name":"FightMND","award":["DIS-202303-00932"],"award-info":[{"award-number":["DIS-202303-00932"]}]},{"DOI":"10.13039\/100016887","name":"Motor Neurone Disease Research Australia","doi-asserted-by":"crossref","award":["IG1950"],"award-info":[{"award-number":["IG1950"]}],"id":[{"id":"10.13039\/100016887","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016887","name":"Motor Neurone Disease Research Australia","doi-asserted-by":"crossref","award":["IG1950"],"award-info":[{"award-number":["IG1950"]}],"id":[{"id":"10.13039\/100016887","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Brazil Family Program for Neurology"},{"name":"Ross Maclean Fellowship for MND Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-55433-9","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:44:18Z","timestamp":1779889458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of triumeq treatment on a TDP-43 mouse model of amyotrophic Lateral sclerosis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-4814","authenticated-orcid":false,"given":"Megan","family":"Fowler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1080-1472","authenticated-orcid":false,"given":"Jillian M","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7954-5801","authenticated-orcid":false,"given":"Adam","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3482-8741","authenticated-orcid":false,"given":"Mary-Louise","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"55433_CR1","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ene.14393","volume":"27","author":"P Masrori","year":"2020","unstructured":"Masrori, P. & Van Damme, P. Amyotrophic lateral sclerosis: a clinical review. Eur. J. Neurol. 27, 1918\u20131929 (2020).","journal-title":"Eur. J. Neurol."},{"key":"55433_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/bs.irn.2024.02.001","volume":"176","author":"L Castelli","year":"2024","unstructured":"Castelli, L. et al. From use of omics to systems biology: Identifying therapeutic targets for amyotrophic lateral sclerosis. Int. Rev. Neurobiol. 176, 209\u2013268 (2024).","journal-title":"Int. Rev. Neurobiol."},{"key":"55433_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"K Abe","year":"2017","unstructured":"Abe, K. et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16, 505\u2013512 (2017).","journal-title":"Lancet Neurol."},{"key":"55433_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00415-025-12975-8","volume":"272","author":"P Ruffo","year":"2025","unstructured":"Ruffo, P., Traynor, B. J. & Conforti, F. L. Advancements in genetic research and RNA therapy strategies for amyotrophic lateral sclerosis (ALS): current progress and future prospects. J. Neurol. 272, 233. https:\/\/doi.org\/10.1007\/s00415-025-12975-8 (2025).","journal-title":"J. Neurol."},{"key":"55433_CR5","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1212\/WNL.0000000000004606","volume":"89","author":"RP van Eijk","year":"2017","unstructured":"van Eijk, R. P. et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 89, 1915\u20131922 (2017).","journal-title":"Neurology"},{"key":"55433_CR6","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley, S. L. et al. Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection. N. Engl. J. Med. 369, 1807\u20131818 (2013).","journal-title":"N. Engl. J. Med."},{"key":"55433_CR7","doi-asserted-by":"publisher","first-page":"e23790","DOI":"10.1096\/fj.202400558R","volume":"38","author":"C Huang","year":"2024","unstructured":"Huang, C., Hoque, M. T., Qu, Q. R., Henderson, J. & Bendayan, R. Antiretroviral drug dolutegravir induces inflammation at the mouse brain barriers. FASEB J. 38, e23790 (2024).","journal-title":"FASEB J."},{"key":"55433_CR8","unstructured":"Liu, X. et al. Resurrection of endogenous retroviruses during aging reinforces senescence. Cell (2023)."},{"key":"55433_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2353\/ajpath.2007.070182","volume":"171","author":"NJ Cairns","year":"2007","unstructured":"Cairns, N. J. et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol. 171, 227\u2013240 (2007).","journal-title":"Am. J. Pathol."},{"key":"55433_CR10","doi-asserted-by":"publisher","first-page":"e87398","DOI":"10.1371\/journal.pone.0087398","volume":"9","author":"SR Shepheard","year":"2014","unstructured":"Shepheard, S. R., Chataway, T., Schultz, D. W., Rush, R. A. & Rogers, M. L. The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. PLoS One. 9, e87398 (2014).","journal-title":"PLoS One"},{"key":"55433_CR11","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/cne.23763","volume":"523","author":"KS Smith","year":"2015","unstructured":"Smith, K. S., Rush, R. A. & Rogers, M. L. Characterization and changes in neurotrophin receptor p75-expressing motor neurons in SOD1G93AG1H mice. J. Comp. Neurol. 523, 1664\u20131682 (2015).","journal-title":"J. Comp. Neurol."},{"key":"55433_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1212\/WNL.0000000000003741","volume":"88","author":"SR Shepheard","year":"2017","unstructured":"Shepheard, S. R. et al. Urinary p75ECD A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology 88, 1137\u20131143 (2017).","journal-title":"Neurology"},{"key":"55433_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00401-015-1460-x","volume":"130","author":"AK Walker","year":"2015","unstructured":"Walker, A. K. et al. Functional recovery in new mouse models of ALS\/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 130, 643\u2013660. https:\/\/doi.org\/10.1007\/s00401-015-1460-x (2015).","journal-title":"Acta Neuropathol."},{"key":"55433_CR14","unstructured":"Leitner, M., Menzies, S. & Lutz, C. Working with ALS mice: Guidelines for preclinical testing & colony management. The Jackson Laboratory (2009)."},{"key":"55433_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0006-8993(98)01258-X","volume":"835","author":"JN Crawley","year":"1999","unstructured":"Crawley, J. N. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res. 835, 18\u201326 (1999).","journal-title":"Brain Res."},{"key":"55433_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14660820510026162","volume":"6","author":"FJ Miana-Mena","year":"2005","unstructured":"Miana-Mena, F. J. et al. Optimal methods to characterize the G93A mouse model of ALS. Amyotroph. Lateral Scler. 6, 55\u201362 (2005).","journal-title":"Amyotroph. Lateral Scler."},{"key":"55433_CR17","doi-asserted-by":"crossref","unstructured":"Wertman, V., Gromova, A., La Spada, A. R. & Cortes, C. J. Low-cost gait analysis for behavioral phenotyping of mouse models of neuromuscular disease. JoVE (Journal Visualized Experiments), e59878 (2019).","DOI":"10.3791\/59878-v"},{"key":"55433_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/laban0803-48","volume":"32","author":"JL Chew","year":"2003","unstructured":"Chew, J. L. & Chua, K. Y. Collection of mouse urine for bioassays. Lab Anim. 32, 48\u201350 (2003).","journal-title":"Lab Anim."},{"key":"55433_CR19","first-page":"71","volume":"3","author":"X Rao","year":"2013","unstructured":"Rao, X., Huang, X., Zhou, Z. & Lin, X. An improvement of the 2\u02c6 (\u2013delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostatistics Bioinf. biomathematics. 3, 71 (2013).","journal-title":"Biostatistics Bioinf. biomathematics"},{"key":"55433_CR20","doi-asserted-by":"publisher","first-page":"552295","DOI":"10.3389\/fneur.2020.552295","volume":"11","author":"R Tortelli","year":"2020","unstructured":"Tortelli, R. et al. Plasma inflammatory cytokines are elevated in ALS. Front. Neurol. 11, 552295 (2020).","journal-title":"Front. Neurol."},{"key":"55433_CR21","doi-asserted-by":"publisher","first-page":"9094","DOI":"10.1038\/s41598-017-09097-1","volume":"7","author":"Y Hu","year":"2017","unstructured":"Hu, Y. et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci. Rep. 7, 9094 (2017).","journal-title":"Sci. Rep."},{"key":"55433_CR22","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1038\/s41380-023-02036-9","volume":"28","author":"W Luan","year":"2023","unstructured":"Luan, W. et al. Early activation of cellular stress and death pathways caused by cytoplasmic TDP-43 in the rNLS8 mouse model of ALS and FTD. Mol. Psychiatry. 28, 2445\u20132461. https:\/\/doi.org\/10.1038\/s41380-023-02036-9 (2023).","journal-title":"Mol. Psychiatry"},{"key":"55433_CR23","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1007\/s00018-008-8497-0","volume":"65","author":"C Stocking","year":"2008","unstructured":"Stocking, C. & Kozak, C. A. Murine endogenous retroviruses. Cell. Mol. Life Sci. 65, 3383\u20133398. https:\/\/doi.org\/10.1007\/s00018-008-8497-0 (2008).","journal-title":"Cell. Mol. Life Sci."},{"key":"55433_CR24","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1101\/gr.130740.111","volume":"22","author":"J Li","year":"2012","unstructured":"Li, J. et al. Mouse endogenous retroviruses can trigger premature transcriptional termination at a distance. Genome Res. 22, 870\u2013884 (2012).","journal-title":"Genome Res."},{"key":"55433_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/21678421.2019.1632899","volume":"20","author":"J Gold","year":"2019","unstructured":"Gold, J. et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the lighthouse trial. Amyotroph. Lateral Scler. Frontotemporal Degeneration. 20, 595\u2013604 (2019).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degeneration"},{"key":"55433_CR26","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller, T. M. et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099\u20131110 (2022).","journal-title":"N. Engl. J. Med."},{"key":"55433_CR27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nm.3108","volume":"19","author":"H Cho","year":"2013","unstructured":"Cho, H. et al. Differential innate immune response programs in neuronal subtypes determine susceptibility to infection in the brain by positive-stranded RNA viruses. Nat. Med. 19, 458\u2013464 (2013).","journal-title":"Nat. Med."},{"key":"55433_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40478-025-01941-0","volume":"13","author":"MEV Swanson","year":"2025","unstructured":"Swanson, M. E. V. et al. Neuronal TDP-43 aggregation drives changes in microglial morphology prior to immunophenotype in amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 13, 39. https:\/\/doi.org\/10.1186\/s40478-025-01941-0 (2025).","journal-title":"Acta Neuropathol. Commun."},{"key":"55433_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.expneurol.2015.07.019","volume":"273","author":"W Zhao","year":"2015","unstructured":"Zhao, W. et al. TDP-43 activates microglia through NF-\u03baB and NLRP3 inflammasome. Exp. Neurol. 273, 24\u201335 (2015).","journal-title":"Exp. Neurol."},{"key":"55433_CR30","doi-asserted-by":"publisher","first-page":"1402962","DOI":"10.3389\/fneur.2024.1402962","volume":"15","author":"L Lu","year":"2024","unstructured":"Lu, L., Deng, Y. & Xu, R. Current potential therapeutics of amyotrophic lateral sclerosis. Front. Neurol. 15, 1402962 (2024).","journal-title":"Front. Neurol."},{"key":"55433_CR31","doi-asserted-by":"publisher","first-page":"242S","DOI":"10.1212\/WNL.47.6_Suppl_4.242S","volume":"47","author":"L Lacomblez","year":"1996","unstructured":"Lacomblez, L. et al. A confirmatory dose-ranging study of riluzole in ALS. Neurology 47, 242S\u2013250S (1996).","journal-title":"Neurology"},{"key":"55433_CR32","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1111\/ejn.15422","volume":"54","author":"AL Wright","year":"2021","unstructured":"Wright, A. L. et al. Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis. Eur. J. Neurosci. 54, 6237\u20136255 (2021).","journal-title":"Eur. J. Neurosci."},{"key":"55433_CR33","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1080\/21678421.2017.1407796","volume":"19","author":"MC Hogg","year":"2018","unstructured":"Hogg, M. C., Halang, L., Woods, I., Coughlan, K. S. & Prehn, J. H. Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotroph. Lateral Scler. Frontotemporal Degeneration. 19, 438\u2013445 (2018).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degeneration"},{"key":"55433_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/bs.irn.2024.04.008","volume":"176","author":"L De Cock","year":"2024","unstructured":"De Cock, L., Bercier, V. & Van Den Bosch, L. New developments in pre-clinical models of ALS to guide translation. Int. Rev. Neurobiol. 176, 477\u2013524 (2024).","journal-title":"Int. Rev. Neurobiol."},{"key":"55433_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/glia.22601","volume":"62","author":"L T\u00f6nges","year":"2014","unstructured":"T\u00f6nges, L. et al. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia 62, 217\u2013232 (2014).","journal-title":"Glia"},{"key":"55433_CR36","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1474-4422(24)00373-9","volume":"23","author":"JC Koch","year":"2024","unstructured":"Koch, J. C. et al. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 23, 1133\u20131146 (2024).","journal-title":"Lancet Neurol."},{"key":"55433_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/archneur.1993.00540010026013","volume":"50","author":"JI Engelhardt","year":"1993","unstructured":"Engelhardt, J. I., Tajti, J. & Appel, S. H. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol. 50, 30\u201336 (1993).","journal-title":"Arch. Neurol."},{"key":"55433_CR38","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41467-020-15644-8","volume":"11","author":"S Garofalo","year":"2020","unstructured":"Garofalo, S. et al. Natural killer cells modulate motor neuron-immune cell cross talk in models of Amyotrophic Lateral Sclerosis. Nat. Commun. 11, 1773. https:\/\/doi.org\/10.1038\/s41467-020-15644-8 (2020).","journal-title":"Nat. Commun."},{"key":"55433_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2022.06.004","volume":"105","author":"S Garofalo","year":"2022","unstructured":"Garofalo, S. et al. Blocking immune cell infiltration of the central nervous system to tame Neuroinflammation in Amyotrophic lateral sclerosis. Brain. Behav. Immun. 105, 1\u201314. https:\/\/doi.org\/10.1016\/j.bbi.2022.06.004 (2022). https:\/\/doi.org:.","journal-title":"Brain. Behav. Immun."},{"key":"55433_CR40","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1073\/pnas.1815961116","volume":"116","author":"E Coque","year":"2019","unstructured":"Coque, E. et al. Cytotoxic CD8\u2009+\u2009T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc. Natl. Acad. Sci. 116, 2312\u20132317 (2019).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"55433_CR41","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40478-021-01239-x","volume":"9","author":"M Hunter","year":"2021","unstructured":"Hunter, M. et al. Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery. Acta Neuropathol. Commun. 9, 140. https:\/\/doi.org\/10.1186\/s40478-021-01239-x (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"55433_CR42","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1128\/jvi.02154-14","volume":"89","author":"Q Chai","year":"2015","unstructured":"Chai, Q., She, R., Huang, Y. & Fu, Z. F. Expression of Neuronal CXCL10 Induced by Rabies Virus Infection Initiates Infiltration of Inflammatory Cells, Production of Chemokines and Cytokines, and Enhancement of Blood-Brain Barrier Permeability. J. Virol. 89, 870\u2013876. https:\/\/doi.org\/10.1128\/jvi.02154-14 (2015).","journal-title":"J. Virol."},{"key":"55433_CR43","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka, K. et al. The integrated stress response. EMBO Rep. 17, 1374\u20131395. https:\/\/doi.org\/10.15252\/embr.201642195 (2016).","journal-title":"EMBO Rep."},{"key":"55433_CR44","doi-asserted-by":"publisher","first-page":"e66672","DOI":"10.1371\/journal.pone.0066672","volume":"8","author":"S Matus","year":"2013","unstructured":"Matus, S., Lopez, E., Valenzuela, V., Nassif, M. & Hetz, C. Functional contribution of the transcription factor ATF4 to the pathogenesis of amyotrophic lateral sclerosis. PloS one. 8, e66672 (2013).","journal-title":"PloS one"},{"key":"55433_CR45","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/brain\/awac412","volume":"146","author":"YP Chu","year":"2023","unstructured":"Chu, Y. P. et al. Transthyretin attenuates TDP-43 proteinopathy by autophagy activation via ATF4 in FTLD-TDP. Brain 146, 2089\u20132106. https:\/\/doi.org\/10.1093\/brain\/awac412 (2023).","journal-title":"Brain"},{"key":"55433_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.imlet.2020.09.006","volume":"228","author":"D Mukherjee","year":"2020","unstructured":"Mukherjee, D., Bercz, L. S., Torok, M. A. & Mace, T. A. Regulation of cellular immunity by activating transcription factor 4. Immunol. Lett. 228, 24\u201334. https:\/\/doi.org\/10.1016\/j.imlet.2020.09.006 (2020).","journal-title":"Immunol. Lett."},{"key":"55433_CR47","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2337\/db13-0757","volume":"63","author":"Y Iwasaki","year":"2013","unstructured":"Iwasaki, Y. et al. Activating Transcription Factor 4 Links Metabolic Stress to Interleukin-6 Expression in Macrophages. Diabetes 63, 152\u2013161. https:\/\/doi.org\/10.2337\/db13-0757 (2013).","journal-title":"Diabetes"},{"key":"55433_CR48","doi-asserted-by":"publisher","unstructured":"Corne, A., Adolphe, F., Estaquier, J., Gaumer, S. & Corsi, J. M. ATF4 Signaling in HIV-1 Infection: Viral Subversion of a Stress Response Transcription Factor. Biology (Basel). 13. https:\/\/doi.org\/10.3390\/biology13030146 (2024).","DOI":"10.3390\/biology13030146"},{"key":"55433_CR49","doi-asserted-by":"crossref","unstructured":"Manghera, M. & Douville, R. N. Endogenous retrovirus-K promoter: a landing strip for inflammatory transcription factors? Retrovirology 10, 1\u201311 (2013).","DOI":"10.1186\/1742-4690-10-16"},{"key":"55433_CR50","doi-asserted-by":"publisher","first-page":"9338","DOI":"10.1128\/JVI.01503-16","volume":"90","author":"M Manghera","year":"2016","unstructured":"Manghera, M., Ferguson-Parry, J., Lin, R. & Douville, R. N. NF-\u03baB and IRF1 induce endogenous retrovirus K expression via interferon-stimulated response elements in its 5\u2032 long terminal repeat. J. Virol. 90, 9338\u20139349 (2016).","journal-title":"J. Virol."},{"key":"55433_CR51","doi-asserted-by":"publisher","first-page":"e45078","DOI":"10.1371\/journal.pone.0045078","volume":"7","author":"AB Tam","year":"2012","unstructured":"Tam, A. B., Mercado, E. L., Hoffmann, A. & Niwa, M. ER stress activates NF-\u03baB by integrating functions of basal IKK activity, IRE1 and PERK. PloS one. 7, e45078 (2012).","journal-title":"PloS one"},{"key":"55433_CR52","doi-asserted-by":"publisher","unstructured":"Schmitz, M. L., Shaban, M. S., Albert, B. V., G\u00f6k\u00e7en, A. & Kracht, M. The Crosstalk of Endoplasmic Reticulum (ER) Stress Pathways with NF-\u03baB: Complex Mechanisms Relevant for Cancer, Inflammation and Infection. Biomedicines 6 (2018). https:\/\/doi.org\/10.3390\/biomedicines6020058","DOI":"10.3390\/biomedicines6020058"},{"key":"55433_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3109\/17482960903545334","volume":"11","author":"AC Ludolph","year":"2010","unstructured":"Ludolph, A. C. et al. Guidelines for preclinical animal research in ALS\/MND: A consensus meeting. Amyotroph. Lateral Scler. 11, 38\u201345 (2010).","journal-title":"Amyotroph. Lateral Scler."},{"key":"55433_CR54","unstructured":"Gubernick, S. I., F\u00e9lix, N., Lee, D., Xu, J. J. & Hamad, B. (Nature Publishing Group, (2016)."},{"key":"55433_CR55","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1128\/AAC.49.6.2504-2506.2005","volume":"49","author":"EV Capparelli","year":"2005","unstructured":"Capparelli, E. V. et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob. Agents Chemother. 49, 2504\u20132506 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"55433_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archneurol.2007.31","volume":"65","author":"S Letendre","year":"2008","unstructured":"Letendre, S. et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65, 65\u201370 (2008).","journal-title":"Arch. Neurol."},{"key":"55433_CR57","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.virol.2016.11.013","volume":"501","author":"S Hu","year":"2017","unstructured":"Hu, S. et al. A humanized mouse model for HIV-2 infection and efficacy testing of a single-pill triple-drug combination anti-retroviral therapy. Virology 501, 115\u2013118 (2017).","journal-title":"Virology"},{"key":"55433_CR58","doi-asserted-by":"publisher","first-page":"617149","DOI":"10.3389\/fphar.2020.617149","volume":"11","author":"L Chen","year":"2021","unstructured":"Chen, L., Al-Harthi, L. & Hu, X. T. Triumeq increases excitability of pyramidal neurons in the medial prefrontal cortex by facilitating voltage-gated Ca2\u2009+\u2009channel function. Front. Pharmacol. 11, 617149 (2021).","journal-title":"Front. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55433-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55433-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55433-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:04:30Z","timestamp":1786017870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55433-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55433"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55433-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments involving mice were approved by the Flinders University Animal Welfare Committee (Ethics #2931) and breeding of mice at the University of Queensland (UQ Animal Ethics Committee approval 2021-AE000200) were conducted under the National Health and Medical Research Council, Australian code for the care and use of animals for scientific purposes.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24283"}}